Shots:

• Roche to acquire all outstanding shares of GenMark’s for $24.05/ share in cash- making a total deal value of $1.8B with a premium of ~43% to GenMark’s closing price on Feb 10- 2021. The acquisition is expected to be completed in Q2’21
• The acquisition will boost Roche’s molecular diagnostics portfolio and will expand the global reach of GenMark’s products
• GenMark deliver molecular diagnostic tests designed to detect multiple pathogens from a single patient sample and its respiratory pathogen panels complement Roche’s COVID-19 diagnostics solutions

 ­ Ref: GlobeNewswire | Image: Roche